For those based in Boston, please look closely at the future meetings list: a 7 Dec 2018 BAARN meeting date has been announced.
Dear All: On 21 Nov 2018, the Decision Support Unit (DSU) of UK NICE and the ABPI are sponsoring a one-day workshop entitled “NICE/DSU/ABPI Masterclass: Using non-randomised data to estimate treatment effects in NICE submissions.”
As the antibacterial world is increasingly engaged with using relatively limited size datasets in settings where control data are also sometimes limited, I thought this looked fascinating and that some of us might want to attend. Although it will naturally have a NICE-specific angle, the observations from NICE would certainly have relevance elsewhere. Here’s the link for more details and here’s a bit of the further description you’ll find at that link:
This masterclass has been developed for those who are currently involved in developing submissions to the NICE technology appraisals programme. It is suitable for those who are familiar with economic evaluation and the requirements of the NICE Guide to the Methods of Technology Appraisal. It does not require any specific statistical knowledge but will assume that attendees are familiar with simple concepts like regression. This masterclass is an opportunity to hear directly from members of the NICE Decision Support Unit and other leading HTA experts on:
- The features of non-RCT evidence that require particular consideration when estimating treatment effects
- Which methods have been used to date in technology appraisals and how the Appraisal Committee’s have received these
- The key features of the range of available methods
- How to select methods from the menu of available options
All sessions will consist of a formal presentation followed by small group discussions centred around real-life examples. The day will also include information on the NICE Observational Data Unit.
All best wishes, –jr
John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: https://13.43.35.2/blog/
Opportunities of interest for the AMR community
- 11 Oct 2018 deadline: Novo’s REPAIR Impact fund has re-opened for proposals during the window 4 Sep – 11 Oct. Read more and apply here.
- 24 Oct 2018 deadline: IMI AMR Accelerator programme Pillar A within IMI Call 15: Capability-building network to manage the whole accelerator and strengthen AMR science. This is a two-stage call, with letter of intent from applicants expected on 24 Oct 2018.
- 24 Oct 2018 deadline: IMI AMR Accelerator programme Pillar B: Tuberculosis drug development network within IMI Call 15: Tuberculosis drug development network to collaboratively progress TB compounds and validate new tools for TB drug development. This is a two-stage call, with letter of intent from applicants expected on 24 Oct 2018.
- 24 Oct 2018 deadline: IMI Call 16: A series of individual programs where a single EFPIA partner works with a consortium to progress compounds for for TB, non-tuberculous mycobacteria, and Gram-negatives. This is a one-stage call, with full proposal from the EFPIA and applicant consortium expected on 24 Oct 2018.
Upcoming meetings of interest to the AMR community:
- 23-26 Sep 2018 (Washington, DC): ASM Conference on Rapid Applied Microbial Next-Generation Sequencing and Bioinformatic Pipelines.
- 24-28 Sep 2018 (Big Sky, Montana): MSG-ERC (Mycoses Study Group) Biennal meeting
- 25 Sep 2018 (New York City): UN General Assembly side-event entitled “Launch of the AMR Challenge.” Sponsored by CDC, BMGF, Pew, Wellcome, and the UN foundation, this is a kick-off event for a year-long effort to encourage commitments to tackling the AMR problem.
- 26 Sep 2018 (Columbus, OH): Open meeting of PACCARB. The available data about the meeting are found here.
- 28 Sep 2018 (New York City): New York Academy of Sciences workshop entitled “Minimizing the Risk of Antimicrobial Resistance from Food Animal Production”
- 3-7 Oct 2018 (San Francisco): ID Week
- 6-14 Oct 2018 International Course on Antibiotics and Resistance (ICARe, Les Pensières, Annecy, France)
- 23 Oct 2018 (New York City): New York Academy of Sciences workshop entitled “New Therapeutic Strategies to Combat Antibacterial Resistance“
- 26 Oct 2018 (London): EMA information day for SMEs: “Regulatory toolbox for medicines and combined devices developers”. Here is the current agenda. Webcast will be available. More details from sme@ema.europa.eu.
- 29-30 Oct 2018 (Washington: BARDA Industry Days, a 2-day conference on countermeasure development for the US Government
- 7-9 Nov 2018 (Seville, Spain): Better Methods for Clinical Studies in Infectious Diseases and Clinical Microbiology: A Hands-on Workshop
- 8 Nov 2018 (Alderley Park, UK): Bionow’s 1-day Bioinfect conference
- 13 Nov 2018 (London): All-Parties Parliamentary Working Group on AMR meeting. Online materials here.
- 16 Nov 2018 (Berlin): Max Planck Institute for Innovation and Competition is organizing a conference on life sciences and innovation. Online materials here.
- [NEW] 21 Nov 2018 (London): NICE- & APBI-sponsored masterclass: “Using non randomised data to estimate treatment effects in NICE submissions”. Details here.
- 29-30 Nov 2018 (Birmingham, UK): BSAC (British Society Antimicrobial Chemotherapy): Antibiotic Resistance Mechanisms Workshop for Researchers
- [NEW] 7 Dec 2018 (Boston, MA) BAARN, Boston Area Antimicrobial Resistance Network 2018 symposium, 8:30am to 7pm at The Starr Center (185 Cambridge Street, Boston, MA). This is an excellent networking opportunity, especially for those based in the Boston area. Details not yet online.
- 14-15 Mar 2019 (Berlin): BEAM– and ND4BB-ENABLE-sponsored Berlin Conference on Novel Antimicrobials and AMR Diagnostics. Details here.
- 21-22 Mar 2019 (Birmingham, UK): BSAC Spring Conference.